대웅제약

069620KOSPI의약품 제조업

60.4 / 100

Reference Date: 2026-07-24

Financial Score23.0 / 40

News Sentiment18.4 / 25

Momentum7.0 / 20

Disclosure12.0 / 15

AI Analysis: ROE significantly exceeds the industry average but the high debt ratio poses financial risk. Rose 8.2% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Daewon Pharmaceutical, established in 2002, is a leading pharmaceutical company specializing in the production and sales of specialty drugs and high-purity botulinum toxin 'Nabohta'. In 2025, it achieved sales of 13.91 trillion KRW and operating profit of 2.04 trillion KRW, driven by global market expansion, AI-based digital healthcare solutions, and R&D investments in innovative drugs.

Number of Employees

1,794people

Average Salary

77.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

7.44Industry Average 11.236.5Point

Lower than industry avg (good)

PBR

1.26Industry Average 0.811.0Point

1.6x industry avg (risky)

ROE

18.71Industry Average 4.017.0Point

4.7x industry avg (excellent)

Debt Ratio

56.35Industry Average 12.430.0Point

4.5x industry avg (risky)

Trend 2023~20258.5 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲6.9% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲26.8% (2-year basis)

ROE Trend

3.5 / 4

Avg ROE 11.9% (improving, 3yr)

Detailed News Sentiment

44 totalPositive 29Neutral 13Negative 2Average Sentiment Score 73.4

Neutral
나보타 매출 1조 넘자 불법 유통도 급증… 대웅제약, AI 모니터링·유...
대웅제약이 나보타의 불법 유통 증가에 대응하여 정품 유통 관리 강화에 나섰으나, 직접적인 주가 영향은 제한적임을 시사.
Neutral
티알, 혁신프리미어 1000 선정…정책금융·부처별 지원사업 우대
티알의 혁신 프리미어 1000 선정은 관련 스타트업에 긍정적 영향을 미칠 수 있으나, 대웅제약과 직접적인 연관성이 없어 중립적 평가.
Negative
대웅제약, 나보타 불법유통 정조준…"정부도 나서달라"
대웅제약의 나보타 불법 유통 차단 노력에도 불구하고, FDA 경고와 관련된 부정적 이슈로 인해 기업 이미지에 부정적 영향이 예상됩니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (19%, downtrend)

Current 123,800Won52-week high 194,00052-week low 107,300

1-month return5.0Point

1m +8.22% (rising)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

4 totalPositive 1Neutral 3Negative 0

Neutral투자판단관련주요경영사항 (펙수클루정(Fexuclue)의 적응증 추가 국내 3상 임상시험계획(IND) 승인(미란성 위식도역류질환 치료 후 유지요법))2026-07-10
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-07
Neutral지속가능경영보고서등관련사항(자율공시)2026-06-30
Positive단일판매ㆍ공급계약체결2026-06-26